- Home
- SRTS vs MIRA Comparison
SRTS vs MIRA Comparison
Compare SRTS & MIRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SRTS | MIRA |
|---|---|---|
| Founded | 2010 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 44.3M | 43.7M |
| IPO Year | 2016 | 2023 |
Fundamental Metrics
Financial Performance| Metric | SRTS | MIRA |
|---|---|---|
| Price | $3.06 | $0.88 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $7.00 | N/A |
| AVG Volume (30 Days) | 24.5K | ★ 60.2K |
| Earning Date | 05-07-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $27,482,000.00 | N/A |
| Revenue This Year | $2.00 | N/A |
| Revenue Next Year | $34.23 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.66 | $0.89 |
| 52 Week High | $5.92 | $2.45 |
Technical Indicators
Market Signals| Indicator | SRTS | MIRA |
|---|---|---|
| Relative Strength Index (RSI) | 54.06 | 42.51 |
| Support Level | $2.87 | N/A |
| Resistance Level | $3.17 | $1.02 |
| Average True Range (ATR) | 0.13 | 0.05 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 55.56 | 14.05 |
Price Performance
Historical ComparisonAbout SRTS Sensus Healthcare Inc.
Sensus Healthcare Inc is engaged in manufacturing a superficial radiotherapy system. These devices are used for treating both oncological and non-oncological skin conditions including basal cell and squamous cell skin cancers and other skin conditions such as keloids. Its product includes SRT-100, SRT-100 vision, and a sentinel service program. The company's revenue is generated majorly from customers in the United States.
About MIRA MIRA Pharmaceuticals Inc.
Mira Pharmaceuticals Inc is a clinical-stage pharmaceutical development company focused on developing novel oral small-molecule therapeutics for neurologic, neuropsychiatric, metabolic, and inflammatory disorders. The company's pipeline includes three product candidates: Ketamir-2, MIRA-55, and SKNY-1, three drug candidates designed to address unmet medical needs across neuropathic and inflammatory pain, central nervous system disorders, and metabolic and behavioral conditions. The company operates as a single operating and reportable segment.